Stay informed about changes in your patient's hemoglobin - in between invasive blood samples.
Capture additional continuous data and feed it securely to the EMR via existing infrastructure.
View trends, key measurement parameters and more, at the bedside and during transport.
February 17th – February 19th | San Diego Convention Center, San Diego, CA | Philips Booth: 1319
Reduces unnecessary transfusions
>87% reduction in transfusion frequency (from 4.5% to 0.6%)1 >90% reduction in average units transfused (from 0.1 to 0.01 units per patient)1
Reduces unnecessary transfusions
> 73% to 32% reduction in the percentage of patients receiving 3 or more units2* > 47% reduction in average units transfused (1.9 to 1.0 per patient)2*
Initiate timely transfusions when transfusions are needed
Philips and Masimo have teamed up to create the future of measurements and monitoring.
Continuous visibility of key patient measurement parameters.
(1) (2) Awada WN et al J Clin Mon it Comput. DOI 10.1007/s10877-015-9660-4. *Study Protocol: In each group, if researchers noted SpHb trended downward below 10 g/dl, a red blood cell transfusion was started and continued until SpHb** trended upward above 10 g/dl. The transfusion threshold of 10 g/dl was predetermined by the study protocol and may not be appropriate for all patients. Blood sampling was the same for the control and test group. Arterial blood was drawn from a 20 gauge radial. **SpHb monitoring is not intended to replace lab testing. Blood samples should be analyzed by lab instruments prior to clinical decision making.
Masimo clinical claims are referenced on this web page. All studies available at www.masimo.com/evidence/featured-studies/feature/
You are about to visit a Philips global content page
Continue